Cancer Research Cancer Research Funding Available  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 4800, May 15, 2007. doi: 10.1158/0008-5472.CAN-06-4473
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fingleton, B.
Right arrow Articles by Matrisian, L. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fingleton, B.
Right arrow Articles by Matrisian, L. M.

Cell, Tumor, and Stem Cell Biology

Loss of Functional Fas Ligand Enhances Intestinal Tumorigenesis in the Min Mouse Model

Barbara Fingleton, Kathy J. Carter and Lynn M. Matrisian

Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee

Requests for reprints: Barbara Fingleton, Department of Cancer Biology, Vanderbilt University Medical Center, 771 PRB, 2220 Pierce Avenue, Nashville, TN 37232. Phone: 615-343-3422; Fax: 615-936-2911; E-mail: Barbara.Fingleton{at}vanderbilt.edu.

Fas ligand (FasL/CD95L), a member of the tumor necrosis factor family, interacts with a specific receptor Fas, ultimately leading to cell death. Tumor expression of FasL has been proposed to aid in immune evasion through a "Fas counterattack" mechanism but has also been described as a proinflammatory factor. Here, we tested the role of FasL in a mouse model of spontaneous tumor development. We used the Min mouse in which multiple benign polyps develop in the intestine due to a mutation in the Apc tumor suppressor gene. Mutant mice deficient in functional FasL, termed gld/gld, were crossed to Min mice to generate tumor-prone animals lacking functional FasL. Comparison of FasL-deficient versus proficient Min mice revealed a significant increase in polyp number in the gld/gld mice. We next assessed immune cell infiltration into adenomas. There was no difference in the number of either lymphocytes or macrophages; however, the number of tumor-infiltrating neutrophils was 3-fold lower in the gld/gld specimens compared with controls. Neutrophil migration in vitro was stimulated by wild-type but not mutant FasL. In a nontumor-bearing colitis model in vivo, neutrophil recruitment to the intestine was also reduced in gld/gld mice. Although the Fas counterattack hypothesis suggests that the absence of FasL would result in increased immune-mediated tumor elimination, the opposite is true in the Min model with lack of functional FasL associated with reduced neutrophil influx and increased tumor development. Thus, the proinflammatory rather than counterattack role of tumor FasL is more relevant. [Cancer Res 2007;67(10):4800–4806]




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
G. T. Stathopoulos, C. Moschos, H. Loutrari, A. Kollintza, I. Psallidas, S. Karabela, S. Magkouta, Z. Zhou, S. A. Papiris, C. Roussos, et al.
Zoledronic Acid Is Effective against Experimental Malignant Pleural Effusion
Am. J. Respir. Crit. Care Med., July 1, 2008; 178(1): 50 - 59.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. J. Sinnamon, K. J. Carter, L. P. Sims, B. LaFleur, B. Fingleton, and L. M. Matrisian
A protective role of mast cells in intestinal tumorigenesis
Carcinogenesis, April 1, 2008; 29(4): 880 - 886.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.